Adjuvant 5-fluorouracil and folinic acid vs observation for pancreatic cancer: composite data from the ESPAC-1 and -3(v1) trials

The ESPAC-1, ESPAC-1 plus, and early ESPAC-3(v1) results (458 randomized patients; 364 deaths) were used to estimate the effectiveness of adjuvant 5FU/FA vs resection alone for pancreatic cancer using meta-analysis. The pooled hazard ratio of 0.70 (95% CI=0.55–0.88) P=0.003, and the median survival...

Descripción completa

Detalles Bibliográficos
Autores principales: Neoptolemos, J P, Stocken, D D, Tudur Smith, C, Bassi, C, Ghaneh, P, Owen, E, Moore, M, Padbury, R, Doi, R, Smith, D, Büchler, M W
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2009
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2625958/
https://www.ncbi.nlm.nih.gov/pubmed/19127260
http://dx.doi.org/10.1038/sj.bjc.6604838
_version_ 1782163444484538368
author Neoptolemos, J P
Stocken, D D
Tudur Smith, C
Bassi, C
Ghaneh, P
Owen, E
Moore, M
Padbury, R
Doi, R
Smith, D
Büchler, M W
author_facet Neoptolemos, J P
Stocken, D D
Tudur Smith, C
Bassi, C
Ghaneh, P
Owen, E
Moore, M
Padbury, R
Doi, R
Smith, D
Büchler, M W
author_sort Neoptolemos, J P
collection PubMed
description The ESPAC-1, ESPAC-1 plus, and early ESPAC-3(v1) results (458 randomized patients; 364 deaths) were used to estimate the effectiveness of adjuvant 5FU/FA vs resection alone for pancreatic cancer using meta-analysis. The pooled hazard ratio of 0.70 (95% CI=0.55–0.88) P=0.003, and the median survival of 23.2 (95% CI=20.1–26.5) months with 5FU/FA vs 16.8 (95% CI=14.3–19.2) months with resection alone supports the use of adjuvant 5FU/FA in pancreatic cancer.
format Text
id pubmed-2625958
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-26259582009-09-21 Adjuvant 5-fluorouracil and folinic acid vs observation for pancreatic cancer: composite data from the ESPAC-1 and -3(v1) trials Neoptolemos, J P Stocken, D D Tudur Smith, C Bassi, C Ghaneh, P Owen, E Moore, M Padbury, R Doi, R Smith, D Büchler, M W Br J Cancer Clinical Study The ESPAC-1, ESPAC-1 plus, and early ESPAC-3(v1) results (458 randomized patients; 364 deaths) were used to estimate the effectiveness of adjuvant 5FU/FA vs resection alone for pancreatic cancer using meta-analysis. The pooled hazard ratio of 0.70 (95% CI=0.55–0.88) P=0.003, and the median survival of 23.2 (95% CI=20.1–26.5) months with 5FU/FA vs 16.8 (95% CI=14.3–19.2) months with resection alone supports the use of adjuvant 5FU/FA in pancreatic cancer. Nature Publishing Group 2009-01-27 2009-01-06 /pmc/articles/PMC2625958/ /pubmed/19127260 http://dx.doi.org/10.1038/sj.bjc.6604838 Text en Copyright © 2009 Cancer Research UK https://creativecommons.org/licenses/by-nc-sa/3.0/This work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/.
spellingShingle Clinical Study
Neoptolemos, J P
Stocken, D D
Tudur Smith, C
Bassi, C
Ghaneh, P
Owen, E
Moore, M
Padbury, R
Doi, R
Smith, D
Büchler, M W
Adjuvant 5-fluorouracil and folinic acid vs observation for pancreatic cancer: composite data from the ESPAC-1 and -3(v1) trials
title Adjuvant 5-fluorouracil and folinic acid vs observation for pancreatic cancer: composite data from the ESPAC-1 and -3(v1) trials
title_full Adjuvant 5-fluorouracil and folinic acid vs observation for pancreatic cancer: composite data from the ESPAC-1 and -3(v1) trials
title_fullStr Adjuvant 5-fluorouracil and folinic acid vs observation for pancreatic cancer: composite data from the ESPAC-1 and -3(v1) trials
title_full_unstemmed Adjuvant 5-fluorouracil and folinic acid vs observation for pancreatic cancer: composite data from the ESPAC-1 and -3(v1) trials
title_short Adjuvant 5-fluorouracil and folinic acid vs observation for pancreatic cancer: composite data from the ESPAC-1 and -3(v1) trials
title_sort adjuvant 5-fluorouracil and folinic acid vs observation for pancreatic cancer: composite data from the espac-1 and -3(v1) trials
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2625958/
https://www.ncbi.nlm.nih.gov/pubmed/19127260
http://dx.doi.org/10.1038/sj.bjc.6604838
work_keys_str_mv AT neoptolemosjp adjuvant5fluorouracilandfolinicacidvsobservationforpancreaticcancercompositedatafromtheespac1and3v1trials
AT stockendd adjuvant5fluorouracilandfolinicacidvsobservationforpancreaticcancercompositedatafromtheespac1and3v1trials
AT tudursmithc adjuvant5fluorouracilandfolinicacidvsobservationforpancreaticcancercompositedatafromtheespac1and3v1trials
AT bassic adjuvant5fluorouracilandfolinicacidvsobservationforpancreaticcancercompositedatafromtheespac1and3v1trials
AT ghanehp adjuvant5fluorouracilandfolinicacidvsobservationforpancreaticcancercompositedatafromtheespac1and3v1trials
AT owene adjuvant5fluorouracilandfolinicacidvsobservationforpancreaticcancercompositedatafromtheespac1and3v1trials
AT moorem adjuvant5fluorouracilandfolinicacidvsobservationforpancreaticcancercompositedatafromtheespac1and3v1trials
AT padburyr adjuvant5fluorouracilandfolinicacidvsobservationforpancreaticcancercompositedatafromtheespac1and3v1trials
AT doir adjuvant5fluorouracilandfolinicacidvsobservationforpancreaticcancercompositedatafromtheespac1and3v1trials
AT smithd adjuvant5fluorouracilandfolinicacidvsobservationforpancreaticcancercompositedatafromtheespac1and3v1trials
AT buchlermw adjuvant5fluorouracilandfolinicacidvsobservationforpancreaticcancercompositedatafromtheespac1and3v1trials

Ejemplares similares